Fluoroscopy Devices Market

Executive Summary

Fluoroscopy Devices Market was valued at US $5.98 billion in 2021 and is projected to grow at 4.83% CAGR over the forecast period to reach US $7.93 billion by 2027. Fluoroscopy Devices Market represented US $0.54 billion opportunity over 2019-2021 and estimated to create US $1.95 billion opportunity in 2027 over 2021.

Fluoroscopy Devices from Consainsights analyses the Fluoroscopy Devices Market in the Life Sciences industry over the forecast period to 2027.

Fluoroscopy Devices research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Fluoroscopy Devices segmentation includes Device Type, Application and Geography.

Based on the Device Type, the Fluoroscopy Devices analysis covers Fixed Fluoroscopes, Mobile Fluoroscopes.

In Device Type segment, Fixed Fluoroscopes segment has highest cagr growth of 4.28%.

Based on the Application, the Fluoroscopy Devices analysis covers Orthopedic, Cardiovascular, Pain Management and Trauma, Neurology, Gastrointestinal, Urology, General Surgery, Other Applications.

In Application segment, Orthopedic segment has highest cagr growth of 4.28%.

Based on the region, the Fluoroscopy Devices analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Canon Medical Systems Corporation, Carestream Health, GE Healthcare (GE Company), Hitachi Medical Systems, Hologic Inc., Koninklijke Philips NV, Orthoscan Inc., Shimadzu Medical, Siemens Healthineers, Varian Medical Systems Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Device Type

Introduction

In 2021, Mobile Fluoroscopes segment has the highest revenue of US $3.20 billion and is expected to grow at CAGR of 4.28% by 2027 Fixed Fluoroscopes segment has highest cagr growth of 4.28%.

Fixed Fluoroscopes

Fixed Fluoroscopes segment was valued at US $2.53 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $3.69 billion by 2027. Fixed Fluoroscopes segment represented US $0.25 billion opportunity over 2019-2021 and estimated to create US $0.91 billion opportunity in 2027 over 2021.

Mobile Fluoroscopes

Mobile Fluoroscopes segment was valued at US $2.91 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $4.24 billion by 2027. Mobile Fluoroscopes segment represented US $0.29 billion opportunity over 2019-2021 and estimated to create US $1.05 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Orthopedic segment has the highest revenue of US $2.31 billion and is expected to grow at CAGR of 4.28% by 2027 Orthopedic segment has highest cagr growth of 4.28%.

Orthopedic

Orthopedic segment was valued at US $2.10 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $3.06 billion by 2027. Orthopedic segment represented US $0.21 billion opportunity over 2019-2021 and estimated to create US $0.76 billion opportunity in 2027 over 2021.

Cardiovascular

Cardiovascular segment was valued at US $1.37 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $2.00 billion by 2027. Cardiovascular segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.49 billion opportunity in 2027 over 2021.

Pain Management and Trauma

Pain Management and Trauma segment was valued at US $0.81 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $1.19 billion by 2027. Pain Management and Trauma segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.29 billion opportunity in 2027 over 2021.

Neurology

Neurology segment was valued at US $0.53 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $0.78 billion by 2027. Neurology segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

Gastrointestinal

Gastrointestinal segment was valued at US $0.30 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $0.44 billion by 2027. Gastrointestinal segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.11 billion opportunity in 2027 over 2021.

Urology

Urology segment was valued at US $0.14 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $0.20 billion by 2027. Urology segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

General Surgery

General Surgery segment was valued at US $0.15 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $0.22 billion by 2027. General Surgery segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.05 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $0.03 billion in 2019 and is projected to grow at 4.28% CAGR over the forecast period to reach US $0.05 billion by 2027. Other Applications segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.